Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03608241 · ClinicalTrials.gov registry record · Phase 1
A Study TO Estimate THE Effect OF PF-06651600 ON THE Pharmacokinetics (PK) OF Oral Contraceptive (OC)
A Phase 1 study of Healthy Females, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT03608241 is a Phase 1 study of Healthy Females that has completed, run by Pfizer. The registered enrollment target is 12 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT03608241, a Phase 1 study of Healthy Females, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of multiple dose PF-06651600 on single dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences.
Conditions Studied
Interventions
- DRUG PF-06651600
- DRUG Ethinyl estradiol (EE) and levonogestrel (LN)
Study Locations (2)
Florida
- Quotient Sciences - Coral Gables
- Quotient Sciences-Miami, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2018-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03608241
The ClinicalTrials.gov registry entry for NCT03608241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Females appearing as the primary indexed condition, and to 2 interventions - of which PF-06651600 is the first listed.
NCT03608241 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03608241 about?
NCT03608241 is a clinical study titled "A Study TO Estimate THE Effect OF PF-06651600 ON THE Pharmacokinetics (PK) OF Oral Contraceptive (OC)". This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of multiple dose PF-06651600 on single dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences.
What is the current status of trial NCT03608241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-09-21. Estimated completion is 2018-11-23.
What conditions does trial NCT03608241 study?
This clinical trial studies the following conditions: Healthy Females.
What interventions are being tested in trial NCT03608241?
The interventions under investigation include: PF-06651600 (DRUG), Ethinyl estradiol (EE) and levonogestrel (LN) (DRUG).
Who is sponsoring clinical trial NCT03608241?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03608241 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Females
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.